Search results
3 cze 2022 · The development of second-generation leuprorelin acetate (LA) depot formulation (Eligard®, Recordati S.p.A) allowed a consistent and controlled release of leuprorelin between injections and a more efficient reduction of testosterone levels with respect to conventional LHRH agonists. Areas covered.
17 sie 2022 · Both gonadotropins stimulate genital organs to produce sex steroid hormones. Several GnRH agonists (such as leuprorelin, buserelin, goserelin, triptorelin, and nafarelin) were synthesized with enhanced biological potency and longer half-lives . At small doses, these agonists stimulate the secretion of gonadotropins and sex hormones.
1 sty 2020 · This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for...
6 cze 2023 · Go to: Abstract. Context. Treatment options for central precocious puberty (CPP) are important for individualization of therapy. Objective. We evaluated the efficacy and safety of 6-month 45-mg leuprolide acetate (LA) depot with intramuscular administration. Methods.
Leuprorelin acetate is being developed as an adjuvant treatment given by subcutaneous injection for pre and perimenopausal women with advanced breast cancer suitable for hormonal manipulation.
1 cze 2023 · Treatment results in hormonal suppression, cessation of pubertal development, and normalization of growth and skeletal maturation rates. Leuprolide acetate was the first GnRH agonist used for the treatment of CPP ( 22 , 23 ).
View leuprorelin acetate information, including dose, uses, side-effects, pregnancy, breast feeding, contra-indications, monitoring requirements and directions for administration.
